BACKGROUND: The renal dopaminergic system plays an important role in the pathogenesis of hypertension. Dopamine D1-like receptors (D1R and D5R) decrease reactive oxygen species (ROS) production via inhibition of pro-oxidant enzymes such as NADPH oxidase. Paraoxonase 2 (PON2) is also involved in the inhibition of NADPH oxidase activity. Therefore, we tested the hypothesis that D1R and D5R inhibit ROS production by increasing the expression of PON2, including those in membrane microdomains. METHODS AND RESULTS: PON2 colocalized with D1R and D5R in mouse renal proximal tubules (RPTs), human RPT (hRPT) cells, and HEK293 cells heterologously expressing human D1R (HEK-hD1R) or D5R (HEK-hD5R). Fenoldopam, an agonist for both D1R and D5R, increased PON2 co-immunoprecipitation with D1R and D5R in HEK-hD1R and HEK-hD5R cells, respectively. Silencing PON2 increased ROS production and NADPH oxidase activity, and impaired the inhibitory effect of fenoldopam. Fenoldopam increased PON2 protein in both lipid rafts (LRs) and non-LRs in HEK-hD1R cells, but only in non-LRs in HEK-hD5R and hRPT cells. Long-term (hrs) fenoldopam stimulation increased PON2 protein in a time-dependent manner in HEK-hD5R, but not in HEK-hD1R cells. Because the effects of fenoldopam on non-LR and total PON2 expressions were similar in HEK-hD5R and hRPT cells, additional studies were performed to determine the relationship between D5R and PON2. Renal PON2 protein was decreased in D5(-/-) mice. In hRPT cells, silencing D5R decreased PON2 expression and increased ROS production. CONCLUSIONS: We conclude that D1-like receptors inhibit ROS production by altering PON2 distribution in membrane microdomains in the short-term, and by increasing PON2 expression in the long-term.
BACKGROUND: The renal dopaminergic system plays an important role in the pathogenesis of hypertension. Dopamine D1-like receptors (D1R and D5R) decrease reactive oxygen species (ROS) production via inhibition of pro-oxidant enzymes such as NADPH oxidase. Paraoxonase 2 (PON2) is also involved in the inhibition of NADPH oxidase activity. Therefore, we tested the hypothesis that D1R and D5R inhibit ROS production by increasing the expression of PON2, including those in membrane microdomains. METHODS AND RESULTS:PON2 colocalized with D1R and D5R in mouse renal proximal tubules (RPTs), human RPT (hRPT) cells, and HEK293 cells heterologously expressing human D1R (HEK-hD1R) or D5R (HEK-hD5R). Fenoldopam, an agonist for both D1R and D5R, increased PON2 co-immunoprecipitation with D1R and D5R in HEK-hD1R and HEK-hD5R cells, respectively. Silencing PON2 increased ROS production and NADPH oxidase activity, and impaired the inhibitory effect of fenoldopam. Fenoldopam increased PON2 protein in both lipid rafts (LRs) and non-LRs in HEK-hD1R cells, but only in non-LRs in HEK-hD5R and hRPT cells. Long-term (hrs) fenoldopam stimulation increased PON2 protein in a time-dependent manner in HEK-hD5R, but not in HEK-hD1R cells. Because the effects of fenoldopam on non-LR and total PON2 expressions were similar in HEK-hD5R and hRPT cells, additional studies were performed to determine the relationship between D5R and PON2. Renal PON2 protein was decreased in D5(-/-) mice. In hRPT cells, silencing D5R decreased PON2 expression and increased ROS production. CONCLUSIONS: We conclude that D1-like receptors inhibit ROS production by altering PON2 distribution in membrane microdomains in the short-term, and by increasing PON2 expression in the long-term.
Authors: S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman Journal: Arterioscler Thromb Vasc Biol Date: 2001-04 Impact factor: 8.311
Authors: Sven Horke; Ines Witte; Petra Wilgenbus; Maximilian Krüger; Dennis Strand; Ulrich Förstermann Journal: Circulation Date: 2007-04-02 Impact factor: 29.690
Authors: Xiaoyan Wang; Yingjin Luo; Crisanto S Escano; Zhiwei Yang; Laureano Asico; Hewang Li; John E Jones; Ines Armando; Quansheng Lu; David R Sibley; Gilbert M Eisner; Pedro A Jose Journal: Hypertension Date: 2010-04-19 Impact factor: 10.190
Authors: Andrew C Tiu; Jian Yang; Laureano D Asico; Prasad Konkalmatt; Xiaoxu Zheng; Santiago Cuevas; Xiaoyan Wang; Hewang Lee; Momina Mazhar; Robin A Felder; Pedro A Jose; Van Anthony M Villar Journal: FASEB J Date: 2020-04-07 Impact factor: 5.191
Authors: Joanne J Liu; Adrienne Hezghia; Saame Raza Shaikh; Joshua F Cenido; Ruth E Stark; J John Mann; M Elizabeth Sublette Journal: Neuropsychopharmacology Date: 2018-06-28 Impact factor: 7.853
Authors: Robin A Felder; John J Gildea; Peng Xu; Wei Yue; Ines Armando; Robert M Carey; Pedro A Jose Journal: Curr Hypertens Rep Date: 2022-06-16 Impact factor: 4.592
Authors: Jacqueline M Garrick; Khoi Dao; Rian de Laat; John Elsworth; Toby B Cole; Judit Marsillach; Clement E Furlong; Lucio G Costa Journal: Chem Biol Interact Date: 2016-04-07 Impact factor: 5.192
Authors: Hewang Lee; Xiaoliang Jiang; Imran Perwaiz; Peiying Yu; Jin Wang; Ying Wang; Maik Hüttemann; Robin A Felder; David R Sibley; Brian M Polster; Selim Rozyyev; Ines Armando; Zhiwei Yang; Peng Qu; Pedro A Jose Journal: Hypertens Res Date: 2021-04-05 Impact factor: 5.528
Authors: Alejandro Olivares-Hernández; Luis Figuero-Pérez; Juan Jesus Cruz-Hernandez; Rogelio González Sarmiento; Ricardo Usategui-Martin; José Pablo Miramontes-González Journal: Biomolecules Date: 2021-02-10
Authors: Jacqueline M Garrick; Toby B Cole; Theo K Bammler; James W MacDonald; Judit Marsillach; Clement E Furlong; Lucio G Costa Journal: Neurotoxicol Teratol Date: 2021-07-01 Impact factor: 4.071